# A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

> **NCT05904470** · PHASE2 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 275 (actual)

## Conditions studied

- Chronic Hepatitis C Virus
- Hepatitis C, Chronic
- Hepatitis C
- Hepatic Cirrhosis
- HCV

## Interventions

- **DRUG:** Bemnifosbuvir
- **DRUG:** Ruzasvir

## Key facts

- **NCT ID:** NCT05904470
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-30
- **Primary completion:** 2024-12-09
- **Final completion:** 2025-01-28
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904470, "A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05904470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*